June 11, 2020 / 12:52 PM / 22 days ago

BRIEF-Lannett Anticipates Biosimilar Application For Insulin Glargine To Be Submitted By 2022 End

June 11 (Reuters) - Lannett Company Inc:

* LANNETT PROVIDES UPDATE ON CLINICAL ADVANCEMENT OF BIOSIMILAR INSULIN GLARGINE, FOLLOWING FDA MEETING

* LANNETT COMPANY INC - ANTICIPATES BIOSIMILAR APPLICATION FOR INSULIN GLARGINE TO BE SUBMITTED BY END OF CALENDAR YEAR 2022

* LANNETT - FDA PROVIDED POSITIVE FEEDBACK ON CLINICAL AND CMC ADVANCEMENT OF BIOSIMILAR INSULIN GLARGINE THAT WAS CONSISTENT WITH CO’S EXPECTATIONS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below